Bicycle Therapeutics (BCYC) Total Non-Current Liabilities (2018 - 2026)

Bicycle Therapeutics (BCYC) has 9 years of Total Non-Current Liabilities data on file, last reported at $95.4 million in Q2 2026.

• Quarterly Total Non-Current Liabilities fell 41.16% year-over-year to $95.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $95.4 million (down 41.16% YoY) and the FY2025 annual result came in at $106.6 million, down 34.48% from the prior year.
• Total Non-Current Liabilities retreated to $95.4 million in Q2 2026, from $97.1 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $229.7 million in Q2 2023 to a low of $95.4 million in Q2 2026.
• A 5-year average of $155.7 million and a median of $152.1 million in 2024 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2023 — Total Non-Current Liabilities surged 75.6% — and 2026, when it slumped 41.16%.
• Tracing BCYC's Total Non-Current Liabilities over 5 years: stood at $136.0 million in 2022, then jumped by 61.65% to $219.8 million in 2023, then declined by 26.0% to $162.7 million in 2024, then sank by 34.48% to $106.6 million in 2025, then retreated by 10.5% to $95.4 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $95.4 million (Q2 2026), $97.1 million (Q1 2026), and $106.6 million (Q4 2025), per Business Quant data.